HSBC TUR.WAR.OP.END. NOVA/ DE000HS9C0J1 /
17/09/2024 17:36:58 | Chg.- | Bid19:12:49 | Ask19:12:49 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.3000EUR | - | - Bid Size: 25,000 |
- Ask Size: 25,000 |
Novo Nordisk | 132.1619 - | 31/12/2078 | Call |
Newsfile Corp
28/08
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
28/08
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...
GlobeNewswire
28/08
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
GlobeNewswire
27/08
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
26/08
Dewpoint Therapeutics Awarded Target ALS Grant for the Second Time for Development of c-mods for Amy...
GlobeNewswire
21/08
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
GlobeNewswire
14/08
19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. Georg...
GlobeNewswire
06/08
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
01/08
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Dire...
GlobeNewswire
11/07
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansio...
GlobeNewswire
11/07
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...
GlobeNewswire
11/07
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...